A recent study by Munné et al. portrayed a protocol to retrieve in vivo produced blastocysts after IUI and uterine lavage for preimplantation genetic testing (PGT) purposes. The authors claimed this protocol might represent a reasonable future perspective for patients who do not want to undergo IVF, but still want to be informed about their embryos’ genetic/chromosomal defects. Although the intent of making PGT available also to patients who cannot or do not need to undergo IVF is respectable, the value of this study is undermined by severe technical and ethical issues. Munné and colleagues’ paper was discussed within the executive committee (i.e., president and vice-president of the society, director and vice-director of the scientific committee, secretariat, and counselors), the special interest group in reproductive genetics, the scientific committee, and the collegio dei probiviri of the Italian Society of Embryology, Reproduction and Research (SIERR). The points raised from this discussion are summarized in this opinion paper.

Munné等人的最新研究。描绘了一种协议，用于在人工授精和子宫灌洗后取回体内产生的胚泡，以进行植入前基因测试（PGT）。作者声称，对于不想进行体外受精但仍希望了解其胚胎的遗传/染色体缺陷的患者，该方案可能代表了合理的未来前景。尽管向不能或不需要进行IVF的患者提供PGT的意图是值得尊重的，但该研究的价值却受到严重的技术和道德问题的损害。Munné及其同事的论文在生殖遗传学特别兴趣小组的执行委员会（即，该学会的主席和副主席，科学委员会的主任和副主任，秘书处和顾问）中进行了讨论，科学委员会以及意大利胚胎学，生殖与研究学会（SIERR）的collegio dei probiviri。这篇意见书总结了这次讨论提出的观点。